C
Cristian Massacesi
Researcher at Novartis
Publications - 66
Citations - 3907
Cristian Massacesi is an academic researcher from Novartis. The author has contributed to research in topics: Metastatic breast cancer & Cancer. The author has an hindex of 23, co-authored 65 publications receiving 3326 citations. Previous affiliations of Cristian Massacesi include Pfizer.
Papers
More filters
Journal ArticleDOI
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria,Daniel Shao-Weng Tan,Rita Chiari,Yi-Long Wu,Luis Paz-Ares,Juergen Wolf,Sarayut Lucien Geater,Sergey Orlov,Diego Cortinovis,Chong-Jen Yu,Maximillian Hochmair,Alexis B. Cortot,Chun-Ming Tsai,Denis Moro-Sibilot,Rosario Garcia Campelo,Tracey McCulloch,Paramita Sen,Margaret Dugan,Serafino Pantano,Fabrice Branle,Cristian Massacesi,Gilberto de Castro +21 more
TL;DR: First-line ceritinib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC.
Journal ArticleDOI
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw,Tae Min Kim,Lucio Crinò,Cesare Gridelli,Katsuyuki Kiura,Geoffrey Liu,Silvia Novello,Alessandra Bearz,Oliver Gautschi,Tony Mok,Makoto Nishio,Giorgio V. Scagliotti,David R. Spigel,S. Deudon,Cheng Zheng,Serafino Pantano,Patrick Urban,Cristian Massacesi,Kalyanee Viraswami-Appanna,Enriqueta Felip +19 more
TL;DR: Ceritinib showed a significant improvement in median progression-free survival compared with chemotherapy and was compared with single-agent chemotherapy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy.
Journal ArticleDOI
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga,Seock–Ah –A Im,Hiroji Iwata,Javier Cortes,Michele De Laurentiis,Zefei Jiang,Carlos L. Arteaga,Walter Jonat,Mark Clemons,Yoshinori Ito,Ahmad Awada,Stephen Chia,Agnieszka Jagiełło-Gruszfeld,Barbara Pistilli,Ling Ming Tseng,Sara A. Hurvitz,Norikazu Masuda,Masato Takahashi,Peter Vuylsteke,Soulef Hachemi,Bharani Dharan,Emmanuelle di Tomaso,Patrick Urban,Cristian Massacesi,Mario Campone +24 more
TL;DR: This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in patients with advanced breast cancer, including an evaluation of the PI3K pathway activation status as a biomarker for clinical benefit.
Journal Article
Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients
Daniele Santini,Bruno Vincenzi,Giordano Dicuonzo,Giuseppe Avvisati,Cristian Massacesi,Fabrizio Battistoni,Michele Gavasci,Laura Rocci,Maria Cristina Tirindelli,Vittorio Altomare,Massimo Tocchini,Maurizio Bonsignori,Giuseppe Tonini +12 more
TL;DR: This study confirms that zoledronic acid could have an in vivo antiangiogenic property through a significant and long-lasting reduction in serum VEGF levels.
Journal ArticleDOI
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
Fabrice Andre,Mario Campone,Ruth O'Regan,C. Manlius,Cristian Massacesi,Tarek Sahmoud,Pabak Mukhopadhyay,Jean-Charles Soria,Michael Naughton,Sara A. Hurvitz +9 more
TL;DR: Everolimus combined with weekly paclitaxel and trastuzumab was generally well tolerated and had encouraging antitumor activity in patients with trastizumab-pretreated and -resistant metastatic HER2-overexpressing breast cancer.